[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"joint-infection\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:joint-infection":20},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,5,0,[8,34,67,97,119],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":4,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":4,"targetDuration":4,"studyType":17,"phases":4,"briefSummary":18,"conditions":19,"keywords":21,"overallStatus":25,"whyStopped":4,"lastUpdateSubmitDate":26,"lastUpdatePostDateStruct":27,"startDateStruct":4,"completionDateStruct":4,"leadSponsor":30,"locationsCount":33},"100577428","bacteriophage-clinical-trial-for-periprosthetic-joint-infection-of-multidrug-resistant-pseudomonas-aeruginosa-100577428",false,"NCT06798168","Bacteriophage Clinical Trial for Periprosthetic Joint Infection of Multidrug Resistant Pseudomonas Aeruginosa","Inclusion Criteria:\n\n* Patient is clinically stable and independently mobile\n* Patient has been diagnosed with a multidrug resistant chronic bacterial PJI and has exhausted all other non-debilitating treatment options (including DAIR and antibiotic therapy)\n\nExclusion Criteria:\n\n* Patient has cultured multiple bacteria and it is difficult for physicians to determine which bacteria is causing the disease\n* Patient develops a life threatening condition or a condition that leads to deterioration of the patients medical condition and that is unrelated to the known PJI as cerebrovascular accident, angina, cancer.\n* Patient's clinical condition is no longer stable and deteriorating for example, if the patient develops sepsis secondary to PJI prior to the commencement of the phage therapy.","FEMALE","18 Years","EXPANDED_ACCESS","This is a single patient study (SPS) that aims to test the bacteriophage treatment as an experimental treatment on a patient suffering from chronic periprosthetic joint infection (PJI) of the right hip. This patients has been suffering from an infection in the right sided hip arthroplasty with a multidrug resistant (MDR) strain of Pseudomonas aeruginosa bacteria. All treatment options for this type of infection have been exhausted. If this patient remains without treatment then there is a high risk of mortality secondary to sepsis and the only remaining surgical option for this patient is a hind quarter amputation which will be a devastating surgery that will largely affect this patients quality of life. However, a large number of published case series have shown the positive impact of combining bacteriophage therapy with antibiotics to achieve a synergistic antibacterial effect and overcome possible resistance development to clear the infection. Therefore the investigators intend to try the bacteriophage therapy on this patients infected hip in the aim to control the infection and improve the patients quality of life.",[20],"Joint Infection",[22,23,24],"Phage therapy","Periprosthetic Joint Infection","Bacteriophage","AVAILABLE","2026-06-01",{"date":28,"type":29},"2026-06-04","ACTUAL",{"name":31,"class":32},"Ottawa Hospital Research Institute","OTHER",1,{"id":35,"slug":36,"hasResults":11,"nctId":37,"briefTitle":38,"officialTitle":39,"acronym":4,"eligibilityCriteria":40,"healthyVolunteers":11,"sex":41,"minAge":16,"maxAge":4,"enrollmentInfo":42,"targetDuration":4,"studyType":45,"phases":46,"briefSummary":48,"conditions":49,"keywords":54,"overallStatus":57,"whyStopped":4,"lastUpdateSubmitDate":58,"lastUpdatePostDateStruct":59,"startDateStruct":61,"completionDateStruct":63,"leadSponsor":65,"locationsCount":33},"100538631","real-component-vs-all-cement-articulating-spacers-for-periprosthetic-knee-infection-100538631","NCT06293352","Real-component vs All-cement Articulating Spacers for Periprosthetic Knee Infection","Durable, Real-component Antibiotic Spacers vs All-cement Articulating Spacers for the Treatment of Periprosthetic Knee Infection","Inclusion Criteria:\n\n* Patients diagnosed with a chronic periprosthetic joint infection after a primary total knee arthroplasty with plan for explant and placement of an antibiotic spacer\n* PJI defined according to Musculoskeletal Infection Society (MSIS) 2018 Consensus Criteria\n\nExclusion Criteria:\n\n* Patients who are unable to consent\n* Infection at site of revision TKA\n* Soft tissue envelope compromise\n* Allergies to study materials (cement, vancomycin, tobramycin)\n* Incompetent extensor mechanism\n* Extensive bone loss\n\nRandomization-specific exclusion criteria\n\n* Extensive soft tissue defect\n* Extensor mechanism compromise","ALL",{"count":43,"type":44},153,"ESTIMATED","INTERVENTIONAL",[47],"NA","In the US, if an infection in an artificial knee joint doesn't heal with antibiotics alone, the standard treatment is a two-stage revision of the artificial knee. In the first stage, the surgeon will remove the artificial knee and clean out the area around the knee. They will then place an antibiotic spacer. An antibiotic spacer is a type of artificial joint that will release antibiotics into the knee space continuously over time. The spacer allows only very basic function of the knee. The patient may need to use crutches or a walker while the antibiotic spacer is in place. After surgery to place the antibiotic spacer, the surgeon may prescribe a course of antibiotics as well. Because the antibiotic spacer is not as durable as a regular artificial joint, after the infection is gone, another surgery is required to take the spacer out and put a new artificial knee joint in.\n\nThere is another way for artificial joint infections to be treated. This is a one-stage revision. In this treatment, the surgeon will remove the artificial knee and clean out the area around the knee. Then the surgeon will place a new artificial knee in using a special kind of cement that contains antibiotics. The cement will release antibiotics into the knee space continuously over time (the surgeon may prescribe a course of antibiotics as well). The new artificial joint with antibiotic cement will function almost the same as the original artificial knee. This means that while the infection is healing the patient will be able to do most of the regular daily activities. However, the antibiotic cement is not as durable as what is normally used to implant an artificial knee. The artificial knee with the antibiotic cement may need to be replaced with a regular artificial knee. When replacement will need to be done is dependent on patient weight, bone strength and activity level, among other things. When it is time to replace the antibiotic cement artificial knee, the patient will have another surgery where the surgeon will take the antibiotic cement artificial knee and put a new artificial knee joint in.\n\nInvestigators know that both the one- and two-stage revision work equally well to heal the infection, but investigators don't know which patients prefer or which provides better function after many years. This study will randomly assign patients to receive either a one-stage or two-stage revision and then follow them for 5 years to ask them about pain, function, and satisfaction.",[50,51,52,20,53],"Prosthetic-joint Infection","Knee Infection","Arthroplasty Complications","Arthroplasty, Replacement, Knee",[55,56],"randomized trial","patient-reported outcomes","RECRUITING","2026-03-20",{"date":60,"type":29},"2026-03-24",{"date":62,"type":29},"2024-08-08",{"date":64,"type":44},"2026-12",{"name":66,"class":32},"Northwestern University",{"id":68,"slug":69,"hasResults":11,"nctId":70,"briefTitle":71,"officialTitle":71,"acronym":4,"eligibilityCriteria":72,"healthyVolunteers":11,"sex":41,"minAge":4,"maxAge":73,"enrollmentInfo":74,"targetDuration":4,"studyType":45,"phases":76,"briefSummary":77,"conditions":78,"keywords":82,"overallStatus":57,"whyStopped":4,"lastUpdateSubmitDate":87,"lastUpdatePostDateStruct":88,"startDateStruct":90,"completionDateStruct":92,"leadSponsor":94,"locationsCount":96},"100339842","alpha-defensin-and-synovial-proteins-to-improve-detection-of-pediatric-septic-arthritis-100339842","NCT03704766","Alpha-Defensin and Synovial Proteins to Improve Detection of Pediatric Septic Arthritis","Inclusion Criteria- Septic Cases and Inflamed, Non-Septic Comparators:\n\n* Synovial fluid is obtained to assess for infection or inflammatory\u002Frheumatologic disease (all medium and large joints will be included: hip, knee, ankle, shoulder, subtalar, elbow, and wrist joints)\n* Patients with recent antibiotic exposure are eligible to participate but will be analyzed separately\n\nInclusion Criteria- Normative Controls:\n\n* Patients undergoing a procedure unrelated to infection (the procedure may be arthroscopy, or an open or percutaneous bony or soft tissue procedure)\n\nExclusion Criteria- All Participants:\n\n* Family declines to participate\u002Fconsent\n* Patients with a major joint trauma (such as a documented ligament tear or fracture) within the past 8 weeks are not eligible to have that joint aspirated, but could have another joint aspirated\n\nExclusion Criteria- Normative Controls:\n\n* A history of recent infection (within the past 3 months)\n* Received antibiotics in the past 7 days","17 Years",{"count":75,"type":44},442,[47],"Differentiating between septic arthritis and other causes of joint inflammation in pediatric patients is challenging and of the utmost importance because septic arthritis requires surgical debridement as part of the treatment regimen. The current gold standard to diagnose septic arthritis in children is a positive synovial fluid culture; however, joint cultures may take several days to return. If a bacterial infection is present, it requires immediate surgical intervention in order to prevent lasting articular cartilage damage. Frequently surgeons must decide whether to surgically debride a joint before culture results are available. There is no single lab test or clinical feature that reliably indicates bacterial infection over other causes of joint inflammation. The alpha-defensin assay has shown high sensitivity and specificity for joint infection in other studies.The purpose of this study is to determine the sensitivity and specificity of several synovial biomarkers for diagnosing pediatric septic arthritis.",[20,79,80,81],"Infection of Hip Joint (Disorder)","Infection of Shoulder Joint","Septic Arthritis",[83,84,85,86],"synovial biomarkers","alpha-defensin","diagnostics","pediatric","2025-06-17",{"date":89,"type":29},"2025-06-22",{"date":91,"type":29},"2016-06-28",{"date":93,"type":44},"2026-05",{"name":95,"class":32},"Hospital for Special Surgery, New York",3,{"id":98,"slug":99,"hasResults":11,"nctId":100,"briefTitle":101,"officialTitle":102,"acronym":4,"eligibilityCriteria":103,"healthyVolunteers":104,"sex":41,"minAge":4,"maxAge":4,"enrollmentInfo":105,"targetDuration":4,"studyType":45,"phases":107,"briefSummary":108,"conditions":109,"keywords":4,"overallStatus":57,"whyStopped":4,"lastUpdateSubmitDate":110,"lastUpdatePostDateStruct":111,"startDateStruct":113,"completionDateStruct":115,"leadSponsor":117,"locationsCount":96},"100479132","rate-of-total-joint-infection-90-day-after-surgery-following-irrigation-with-next-science-no-rinse-solution-vs-soc-alone-100479132","NCT05519007","Rate of Total Joint Infection 90-day After Surgery Following Irrigation With Next Science No-Rinse Solution vs SOC Alone","Clinical Evaluation of the Rate of Total Joint Infection 90-day After Surgery Following Irrigation With Next Science No-Rinse Solution vs SOC Alone","Inclusion Criteria:\n\n1. Adult that meets at least one of the below criteria at time of screening:\n\n   * American Society of Anesthesiologists (ASA) 3 2\n   * BMI \\>35\n   * Patient with functional limitations as a result of disease1:\n\n     * Poorly treated hypertension\n     * Poorly treated diabetes\n     * Chronic renal failure\n     * Bronchospastic disease\n     * Disease with intermittent exacerbations\n     * Stable angina\n     * Implanted pacemaker\n   * Known history as an active nicotine use (smoker)\n   * Known history of uncontrolled diabetes mellitus (HgbA1C \\> 7.0)\n   * Known history of end stage organ disease\n   * Known history of inflammatory arthritis and currently on rheumatological medication (DMARDs)\n   * Known history of current active cancer treatment (chemotherapy)\n   * Venous Disease (Surgical Risk Calculator from ACS-NSQIP)\n   * Charleston Comorbidity Score \\> 2\n   * Elixhauser Score \\>11\n   * Age 65 or older\n2. Subject is scheduled to primary joint replacement.\n3. Subject is willing and able to comply with all study procedures including transportation to the study site for all scheduled visits and be available for the duration of the study.\n4. Subject has understood, signed, and dated the informed consent form.\n\nExclusion Criteria:\n\n1. Unable to provide signed and dated informed consent.\n2. Unable or unwilling to comply with all study-related procedures.\n3. Known history of allergic reaction to any of the study products or its components, including any products used for standard of care (such as dressings or any coverings)\n4. Subject has contraindications to general anesthesia\n5. Any subject positive for Covid-19 virus at time of surgical screening\n6. Subjects have evidence of prolonged QT segment, per EKG.\n7. Subjects from a vulnerable population, in accordance with 45 CFR 46 Subparts B, C, and D",true,{"count":106,"type":44},936,[47],"A prospective, single-site, double-arm, parallel, interventional, randomized, controlled clinical trial to assess 90-day rate of joint infections in subjects undergoing primary hip replacements after administration of Next Science No-Rinse Solution (hereby referred to as NS) vs SOC (saline irrigation). The Next Science treatment arm will exhibit greater reduction in rate of 90-day post-operative joint infection than SOC (saline) arm",[20],"2025-05-20",{"date":112,"type":29},"2025-05-23",{"date":114,"type":29},"2023-09-26",{"date":116,"type":44},"2026-12-31",{"name":118,"class":32},"Northwell Health",{"id":120,"slug":121,"hasResults":11,"nctId":122,"briefTitle":123,"officialTitle":124,"acronym":4,"eligibilityCriteria":125,"healthyVolunteers":11,"sex":41,"minAge":126,"maxAge":73,"enrollmentInfo":127,"targetDuration":129,"studyType":130,"phases":4,"briefSummary":131,"conditions":132,"keywords":136,"overallStatus":57,"whyStopped":4,"lastUpdateSubmitDate":141,"lastUpdatePostDateStruct":142,"startDateStruct":144,"completionDateStruct":146,"leadSponsor":148,"locationsCount":33},"100579684","initial-oral-antibiotics-for-bone-and-joint-infections-in-children-100579684","NCT06827496","Initial Oral Antibiotics for Bone and Joint Infections in Children","Initial Oral Antibiotics for Bone and Joint Infections in Children: A Prospective Nationwide Real-world Effectiveness Study in Denmark","Children and adolescents aged 3 months to 17 years with uncomplicated bone and joint infections treated with initial oral antibiotics.\n\nAccording to Danish Nationwide Guidelines (initiated in 2024), initial oral antibiotics are recommended to patients with no risk factors for complicated disease. Risk factors include for complicated disease include:\n\n1. Severe illness or sepsis\n2. Rapid symptom progression\n3. Pronounced symptoms, including severe pain\n4. Pronounced soft tissue involvement\n5. Foreign material or post-surgical infection\n6. Infection with a resistent or rare pathogen, e.g., Salmonella or MRSA\n7. Severe comorbidity, including immunodeficiency\n\nPatients who have received intravenous antibiotic therapy for less than 24 h before oral antibiotics will be included","3 Months",{"count":128,"type":44},100,"5 Years","OBSERVATIONAL","Initial oral antibiotic treatment for children and adolescents with uncomplicated bone and joint infections (BJI) has been found non-inferior to initial IV antibiotics in one randomized controlled trial (RCT). The real-world effectiveness of initial oral antibiotics for children and adolescents with BJI is unclear.\n\nThis nationwide, prospective, multicenter, real-world cohort study aims to compare the effectiveness and safety of initial oral antibiotic treatment for children and adolescents with uncomplicated BJI in a real-world setting with those who received initial oral antibiotics in our RCT.",[133,81,134,20,135],"Osteomyelitis Acute","Bone Infection","Bone and Joint Infection",[137,138,139,140],"Bone and joint infections","Children","Oral antibiotics","Osteomyelitis","2025-04-05",{"date":143,"type":29},"2025-04-09",{"date":145,"type":29},"2024-11-15",{"date":147,"type":44},"2027-05",{"name":149,"class":32},"Rigshospitalet, Denmark"]